An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-23

Study Completion Date

2019-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the safety and effectiveness of Losartan potassium in subjects with eosinophilic esophagitis (EoE) including those with a connective tissue disorder (CTD) and those without a CTD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196

Eosinophilic Esophagitis Connective Tissue Disorders

COMPLETED PHASE2

Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

NCT01022970

Eosinophilic Esophagitis

COMPLETED PHASE2

The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors

NCT01404832

Gastroesophageal Reflux Disease Eosinophilic Esophagitis

TERMINATED PHASE4

Outcome of Children With Eosinophilic Esophagitis

NCT06190080

Esophagitis, Eosinophilic

NOT_YET_RECRUITING NA

CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children

NCT03342391

Eosinophilic Esophagitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this research study is to test the safety and effects (good and bad) of Losartan potassium on participants with eosinophilic esophagitis (EoE). If a participant has a connective tissue disorder (CTD) the researchers want to see what effects (good or bad) Losartan has on EoE.

EoE is an inflammatory disease of the esophagus that is typically triggered by exposure to food. Connective tissue disorders (CTDs) are disorders that affect the connective tissues in the body such as tendons and ligaments.

A protein called transforming growth factor (TGF)-beta is associated with both EoE and CTD. Losartan may decrease the amount of TGF-beta and therefore help EoE and CTD.

Losartan is a drug that is approved by the United States Food and Drug Administration (FDA) for use in adults and children over 6 years of age who have high blood pressure. This medication has not been studied in people with EoE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eosinophilic Esophagitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

This study is an open-label study which means that all participants receive the study medicine.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EoE +/- CTD

Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks

Group Type EXPERIMENTAL

Losartan Potassium

Intervention Type DRUG

Losartan potassium

EoE + CTD

Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks

Group Type EXPERIMENTAL

Losartan Potassium

Intervention Type DRUG

Losartan potassium

EoE - CTD

Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks

Group Type EXPERIMENTAL

Losartan Potassium

Intervention Type DRUG

Losartan potassium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Losartan Potassium

Losartan potassium

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Losartan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent/assent
* Confirmed, active EoE (at Screening or within 12 weeks prior to enrollment)
* Does or does not have diagnosis of a connective tissue disorder (CTD)
* Has been on a high dose of proton pump inhibitor (PPI) for at least 8 weeks prior to a diagnostic endoscopy of EoE without histologic resolution (i.e., ≥ 15 eosinophils/HPF).
* Maintain the same diet, swallowed steroid and PPI therapies throughout the duration of the study
* Female participants must be either:

1. Of non-childbearing potential (pre-menarchal or surgically sterile with documentation). OR
2. Have a negative urine pregnancy test at screening and at each monthly study visit.

Exclusion Criteria

* Any past or planned cardiac surgery.
* An aortic root Z-score ≥ 3.0 on a previous echocardiogram.
* Intolerance to Losartan
* A mean blood pressure measurement (both systolic and diastolic) at screening that is below the 2nd percentile for his/her age
* Renal dysfunction
* Another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome, Churg Strauss vasculitis, eosinophilic granuloma, or a parasitic infection).
* A diagnosis of hepatic insufficiency (e.g., liver failure, history of liver transplantation or persistent liver transaminase elevation).
* A history of abnormal gastric or duodenal biopsy or documented gastrointestinal disorders (e.g., Celiac Disease, Crohn's disease or Helicobacter pylori infection), not including chronic gastritis, chronic duodenitis, mucosal eosinophilia or other eosinophilic gastrointestinal disorders (EGIDs).
* Use of anti-immunoglobulin (Ig)E monoclonal antibody (mAb), anti-tumor necrosis factor (TNF) mAb, anti-IL-5 agents, or anti-IL-13 within 6 months prior to study entry
* Use of methotrexate, cyclosporine, interferon α, or other systemic immunosuppressive or immunomodulating agents within 3 months prior to the screening visit.
* A stricture during endoscopy procedure that prevents passage of the endoscope
* Taking or is planning to take an angiotensin receptor blocker (ARB), angiotensin-converting enzyme inhibitor (ACEI), beta blocker (BB), or calcium-channel blocker therapy at the screening visit or at any time during the study or has been taking any of these medications for 3 months prior to the screening visit.
* Taking or planning to take hydrochlorothiazide, digoxin, warfarin, cimetidine, phenobarbital, rifampin, or fluconazole.
* Taking or planning to take potassium supplements or salt substitutes containing potassium.
* A female participant who is pregnant or nursing or, if of childbearing potential, is not using a medically accepted, effective method of birth control (e.g., condom, oral/injectable/subcutaneous contraceptive, intrauterine device, or sexual abstinence).
* Participated/participating in any investigative drug or device study within 30 days prior to study entry.
* Participated/participating in any investigative biologics study within 3 months prior to study entry.
* Unable to be confirmed, active EoE (at Screening or within 12 weeks prior to enrollment)

Minimum Eligible Age

5 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No